Literature DB >> 11932154

Microscopic (R1) and macroscopic (R2) residual disease in patients with resected non-small cell lung cancer.

H S Hofmann1, C Taege, C Lautenschläger, H Neef, R E Silber.   

Abstract

OBJECTIVES: This retrospective study evaluates the probability of survival in patients who had undergone resection for non-small cell lung cancer (NSCLC) and in whom residual disease at the resection margins was found.
METHODS: During a period of 6 years, 596 patients with NSCLC were operated upon with curative intention. Residual disease at the resection margin was divided into microscopic (R1) and macroscopic (R2).
RESULTS: Twenty-six patients (4.4%) showed R1 and 12 (2%) R2 residual disease. An extrabronchial (thoracic wall, vessels) R1 situation was found in five patients and a bronchial R1 infiltration in 21 cases. The bronchial resection margin was subject to peribronchial infiltration in most cases (16/21). A total of 17/21 (65%) patients with bronchial infiltration had N2 disease. Thirty day lethality was 3.8% in the R1 group. Fifteen patients had postoperative irradiation. The 5-year survival rate for patients with R1 resection was 14%. The differences in survival between patients with extrabronchial vs. bronchial infiltration and N0/N1 vs. N2 were significant using univariate analysis. Adjuvant radiation did not result (especially in N2 disease) in a survival benefit. Among 12 patients with macroscopic residual disease (R2), 3/12 (25%) died within the first 30 days after the operation, and none of the R2 patients survived the first year after the operation.
CONCLUSIONS: Patients with an R1 situation have a survival rate of 14% comparable to curative resected patients (RO) in stage III. Adjuvant radiation had no clear effect on survival. Patients with macroscopic tumor (R2) should receive palliative treatment after the operation depending on their condition.

Entities:  

Mesh:

Year:  2002        PMID: 11932154     DOI: 10.1016/s1010-7940(02)00030-1

Source DB:  PubMed          Journal:  Eur J Cardiothorac Surg        ISSN: 1010-7940            Impact factor:   4.191


  10 in total

1.  The influence of adjuvant therapy on survival in patients with indeterminate margins following surgery for non-small cell lung cancer.

Authors:  Vignesh Raman; Oliver K Jawitz; Chi-Fu J Yang; Soraya L Voigt; Anthony W Kim; Betty C Tong; Thomas A D'Amico; David H Harpole
Journal:  J Thorac Cardiovasc Surg       Date:  2019-09-30       Impact factor: 5.209

2.  Results of the Austrian National Lung Cancer Audit.

Authors:  Otto C Burghuber; Klaus Kirchbacher; Andrea Mohn-Staudner; Maximilian Hochmair; Marie-Kathrin Breyer; Michael Studnicka; Michael Rolf Mueller; Petra Feurstein; Andrea Schrott; Bernd Lamprecht; Josef Eckmayr; Friedrich Renner; Josef Bolitschek; Wolfgang Pohl; Peter Schenk; Peter Errhalt; Peter Cerkl; Bernhard Baumgartner; Meinhard Kneussl; Sylvia Hartl
Journal:  Clin Med Insights Oncol       Date:  2020-09-10

3.  Prevalence, Prognostic Implications, and Survival Modulators of Incompletely Resected Non-Small Cell Lung Cancer in the U.S. National Cancer Data Base.

Authors:  Raymond U Osarogiagbon; Chun Chieh Lin; Matthew P Smeltzer; Ahmedin Jemal
Journal:  J Thorac Oncol       Date:  2016-01       Impact factor: 15.609

4.  Accidental invisible intrathoracic disseminated pT4-M1a: a distinct lung cancer with favorable prognosis.

Authors:  Wen-Zhao Zhong; Wei Li; Xue-Ning Yang; Ri-Qiang Liao; Qiang Nie; Song Dong; Hong-Hong Yan; Xu-Chao Zhang; Hai-Yan Tu; Bin-Chao Wang; Jian Su; Jin-Ji Yang; Qing Zhou; Yi-Long Wu
Journal:  J Thorac Dis       Date:  2015-07       Impact factor: 2.895

5.  Concurrent paclitaxel-based chemo-radiotherapy for post-surgical microscopic residual tumor at the bronchial margin (R1 resection) in non-small-cell lung cancer.

Authors:  Meixiang Zhou; Tao Li; Yongmei Liu; Changjin Sun; Na Li; Yong Xu; Jiang Zhu; Zhenyu Ding; Yongsheng Wang; Meijuan Huang; Feng Peng; Jin Wang; Li Ren; You Lu; Youling Gong
Journal:  BMC Cancer       Date:  2015-02-06       Impact factor: 4.430

6.  Supraclavicular lymph node incisional biopsies have no influence on the prognosis of advanced non-small cell lung cancer patients: a retrospective study.

Authors:  Song Dong; Ning Zhao; Wei Deng; Hui-Wen Sun; Fei-Yu Niu; Jin-Ji Yang; Wen-Zhao Zhong; Feng Li; Hong-Hong Yan; Chong-Rui Xu; Qiu-Yi Zhang; Xue-Ning Yang; Ri-Qiang Liao; Qiang Nie; Yi-Long Wu
Journal:  World J Surg Oncol       Date:  2017-01-09       Impact factor: 2.754

7.  Relationship between EGFR gene mutation and local metastasis of resectable lung adenocarcinoma.

Authors:  Yunqiang Nie; Wei Gao; Na Li; Wenjun Chen; Hui Wang; Cuiyun Li; Haiyan Zhang; Ping Han; Yingmei Zhang; Xin Lv; Xinyi Xu; Hongyan Liu
Journal:  World J Surg Oncol       Date:  2017-03-03       Impact factor: 2.754

Review 8.  Prognostic factors in resected lung carcinomas.

Authors:  Keith M Kerr; Marianne C Nicolson
Journal:  EJC Suppl       Date:  2013-09

Review 9.  Near-Infrared Fluorescence Tumor-Targeted Imaging in Lung Cancer: A Systematic Review.

Authors:  Lisanne K A Neijenhuis; Lysanne D A N de Myunck; Okker D Bijlstra; Peter J K Kuppen; Denise E Hilling; Frank J Borm; Danielle Cohen; J Sven D Mieog; Willem H Steup; Jerry Braun; Jacobus Burggraaf; Alexander L Vahrmeijer; Merlijn Hutteman
Journal:  Life (Basel)       Date:  2022-03-17

10.  Postoperative radiotherapy for pathological stage IIIA-N2 non-small cell lung cancer with positive surgical margins.

Authors:  Meng Yuan; Yu Men; Jingjing Kang; Xin Sun; Maoyuan Zhao; Yongxing Bao; Xu Yang; Shuang Sun; Zeliang Ma; Jianyang Wang; Lei Deng; Wenqing Wang; Yirui Zhai; Wenyang Liu; Tao Zhang; Xin Wang; Nan Bi; Jima Lv; Jun Liang; Qinfu Feng; Dongfu Chen; Zefen Xiao; Zongmei Zhou; Luhua Wang; Zhouguang Hui
Journal:  Thorac Cancer       Date:  2020-11-27       Impact factor: 3.223

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.